Volume 8 Issue 2
Dec.  2024
Turn off MathJax
Article Contents
Abstract
References
Related Articles
Lu Chen, Yawen Zhuang, Jingjing Zhang, Yi Zhu. Research Progress in Interactions between Bile Acids, Gastrointestinal Microbes and GPBAR1 in Pancreatic Cancer[J]. Blood&Genomics, 2024, 8(2): 10003. DOI: 10.70322/BG20240210003
Citation: Lu Chen, Yawen Zhuang, Jingjing Zhang, Yi Zhu. Research Progress in Interactions between Bile Acids, Gastrointestinal Microbes and GPBAR1 in Pancreatic Cancer[J]. Blood&Genomics, 2024, 8(2): 10003. DOI: 10.70322/BG20240210003
shu

Research Progress in Interactions between Bile Acids, Gastrointestinal Microbes and GPBAR1 in Pancreatic Cancer

  • 1 Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China;

  • 2 Pancreas Institute of Nanjing Medical University, Nanjing 210029, China;

  • 3 Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Funds: 

This work was supported by the grant from Jiangsu Province Capability Improvement Project through Science, Technology and Education (Jiangsu Provincial Medical Key Discipline, ZDXK202222).

More Information
  • Author Bio:

    Lu Chen,1445159201@qq.com;Yawen Zhuang,15980010709@163.com;Jingjing Zhang,zhangjingjing@njmu.edu.cn

  • Corresponding author:

    Yi Zhu,E-mail:zhuyijssry@njmu.edu.cn

  • Received Date: 2024-09-08
  • Revised Date: 2024-11-07
  • Available Online: 2024-12-26
  • Published Date: 2025-06-14
    Graphical Abstract
    • Abstract
  • Bile acids have traditionally been regarded as a contributing factor in the development of pancreatic cancer. However, the mechanisms by which they induce or promote the progression of pancreatic cancer remain controversial. Additional research is necessary to provide substantial evidence. There is evidence that gastrointestinal microbes involved in bile acid metabolism and thw G protein-coupled bile acid receptor (GPBAR1), which responds to bile acid signals, may collaborate with bile acids in the initiation and progression of pancreatic cancer. This review focuses on the relationships between bile acids, gastrointestinal microbes, GPBAR1 and pancreatic cancer. It aims to interpret the factors influencing the onset and development of pancreatic cancer from a holistic perspective and provide insights towards the treatment of pancreatic cancer.
    • FullText(HTML)
    • References (64)
  • [1]
    . Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in pancreatic cancer. Int. J. Mol. Sci. 2019, 20, 4504
    [2]
    . Zhu S, Yang K, Yang S, Zhang L, Xiong M, Zhang J, et al. A high bile acid environment promotes apoptosis and inhibits migration in pancreatic cancer. Bioengineered 2022, 13, 6719–6728.
    [3]
    . Mohanty I, Allaband C, Mannochio-Russo H, El Abiead Y, Hagey LR, Knight R, et al. The changing metabolic landscape of bile acids - keys to metabolism and immune regulation. Nat. Rev. Gastroenterol Hepatol. 2024, 21, 493–516.
    [4]
    . Fleishman JS, Kumar S. Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets. Signal Transduct. Target Ther. 2024, 9, 97.
    [5]
    . Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J. Hepatol. 2011, 54, 1263–1272.
    [6]
    . McMillan AS, Theriot CM. Bile acids impact the microbiota, host, and C. difficile dynamics providing insight into mechanisms of efficacy of FMTs and microbiota-focused therapeutics. Gut. Microbes. 2024, 16, 2393766.
    [7]
    . Loman BR, Alzoubi Z, Lynch AJ, Jaggers RM, Jordan K, Grant CV, et al. Paclitaxel chemotherapy disrupts microbiota-enterohepatic bile acid metabolism in mice. Gut. Microbes. 2024, 16, 2410475.
    [8]
    . Lee JW, Cowley ES, Wolf PG, Doden HL, Murai T, Caicedo KYO, et al. Formation of secondary allo-bile acids by novel enzymes from gut Firmicutes. Gut. Microbes. 2022, 14, 2132903.
    [9]
    . Spatz M, Ciocan D, Merlen G, Rainteau D, Humbert L, Gomes-Rochette N, et al. Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis. JHEP Rep. 2021, 3, 100230.
    [10]
    . Thibaut MM, Bindels LB. Crosstalk between bile acid-activated receptors and microbiome in entero-hepatic inflammation. Trends. Mol. Med. 2022, 28, 223–236.
    [11]
    . Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat. Rev. Gastroenterol Hepatol. 2018, 15, 111–128.
    [12]
    . Ocvirk S, O'Keefe SJD. Dietary fat, bile acid metabolism and colorectal cancer. Semin. Cancer Biol. 2021, 73, 347–355.
    [13]
    . Grant SM, DeMorrow S. Bile acid signaling in neurodegenerative and neurological disorders. Int. J. Mol. Sci. 2020, 21, 5982.
    [14]
    . Yang Q, Zhang J, Zhu Y. Potential roles of the gut microbiota in pancreatic carcinogenesis and therapeutics. Front. Cell Infect Microbiol. 2022, 12, 872019.
    [15]
    . Bhimanwar RS, Mittal A, Chaudhari S, Sharma V. Recent advancements in the structural exploration of TGR5 agonists for diabetes treatment. RSC Med. Chem. 2024, 15, 3026–3037.
    [16]
    . Sharma B, Twelker K, Nguyen C, Ellis S, Bhatia ND, Kuschner Z, et al. Bile acids in pancreatic carcinogenesis. Metabolites 2024, 14, 348.
    [17]
    . Herschman HR. Function and regulation of prostaglandin synthase 2. Adv. Exp. Med. Biol. 1999, 469, 3–8.
    [18]
    . Cruz MS, Tintelnot J, Gagliani N. Roles of microbiota in pancreatic cancer development and treatment. Gut. Microbes. 2024, 16, 2320280.
    [19]
    . Schwarcz S, Kovács P, Nyerges P, Ujlaki G, Sipos A, Uray K, et al. The bacterial metabolite, lithocholic acid, has antineoplastic effects in pancreatic adenocarcinoma. Cell. Death Discov. 2024, 10, 248.
    [20]
    . Zheng Y, Sun W, Wang Z, Liu J, Shan C, He C, et al. Activation of pancreatic acinar FXR protects against pancreatitis via Osgin1-mediated restoration of efficient autophagy. Research 2022, 2022, 9784081.
    [21]
    . Xu Y, Nipper MH, Dominguez AA, Ye Z, Akanuma N, Lopez K, et al. Reconstitution of human PDAC using primary cells reveals oncogenic transcriptomic features at tumor onset. Nat. Commun. 2024, 15, 818.
    [22]
    . Shen G, Wang Q, Li Z, Xie J, Han X, Wei Z, et al. Bridging chronic inflammation and digestive cancer: the critical role of innate lymphoid cells in tumor microenvironments. Int. J. Biol. Sci. 2024, 20, 4799–4818.
    [23]
    . Yang K, Li X, Xie K. Senescence program and its reprogramming in pancreatic premalignancy. Cell Death Dis. 2023, 14, 528.
    [24]
    . Zi Z, Rao Y. Discoveries of GPR39 as an evolutionarily conserved receptor for bile acids and of its involvement in biliary acute pancreatitis. Sci. Adv. 2024, 10, eadj0146.
    [25]
    . Feng S, Wei Q, Hu Q, Huang X, Zhou X, Luo G, et al. Research progress on the relationship between acute pancreatitis and calcium overload in acinar cells. Dig. Dis. Sci. 2019, 64, 25–38.
    [26]
    . Fanczal J, Pallagi P, Görög M, Diszházi G, Almássy J, Madácsy T, et al. TRPM2-mediated extracellular Ca(2+) entry promotes acinar cell necrosis in biliary acute pancreatitis. J. Physiol. 2020, 598, 1253–1270.
    [27]
    . Hong WL, Huang H, Zeng X, Duan CY. Targeting mitochondrial quality control: new therapeutic strategies for major diseases. Mil. Med. Res. 2024, 11, 59.
    [28]
    . Gu X, Huang Z, Ying X, Liu X, Ruan K, Hua S, et al. Ferroptosis exacerbates hyperlipidemic acute pancreatitis by enhancing lipid peroxidation and modulating the immune microenvironment. Cell Death Discov. 2024, 10, 242.
    [29]
    . Lu S, Wang C, Ma J, Wang Y. Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy. Front. Immunol. 2024, 15, 1456030.
    [30]
    . Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022, 7, 135.
    [31]
    . Xu F, Yang C, Tang M, Wang M, Cheng Z, Chen D, et al. The role of gut microbiota and genetic susceptibility in the pathogenesis of pancreatitis. Gut. Liver. 2022, 16, 686–696.
    [32]
    . Konishi H, Isozaki S, Kashima S, Moriichi K, Ichikawa S, Yamamoto K, et al. Probiotic Aspergillus oryzae produces anti-tumor mediator and exerts anti-tumor effects in pancreatic cancer through the p38 MAPK signaling pathway. Sci. Rep. 2021, 11, 11070.
    [33]
    . Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 2019, 178, 795–806.e12.
    [34]
    . Li K, Xiao Y, Bian J, Han L, He C, El-Omar E, et al. Ameliorative effects of gut microbial metabolite urolithin A on pancreatic diseases. Nutrients 2022, 14, 2549.
    [35]
    . Mirji G, Worth A, Bhat SA, El Sayed M, Kannan T, Goldman AR, et al. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Sci. Immunol. 2022, 7, eabn0704.
    [36]
    . Ruze R, Song J, Yin X, Chen Y, Xu R, Wang C, et al. Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review. Signal Transduct Target Ther. 2023, 8, 139.
    [37]
    . Han ZY, Fu ZJ, Wang YZ, Zhang C, Chen QW, An JX, et al. Probiotics functionalized with a gallium-polyphenol network modulate the intratumor microbiota and promote anti-tumor immune responses in pancreatic cancer. Nat. Commun. 2024, 15, 7096.
    [38]
    . Shrader HR, Miller AM, Tomanek-Chalkley A, McCarthy A, Coleman KL, Ear PH, et al. Effect of bacterial contamination in bile on pancreatic cancer cell survival. Surgery 2021, 169, 617–622.
    [39]
    . Aykut B, Pushalkar S, Chen R, Li Q, Abengozar R, Kim JI, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature 2019, 574, 264–267.
    [40]
    . Guan Z, Luo L, Liu S, Guan Z, Zhang Q, Wu Z, et al. The role of TGR5 as an onco-immunological biomarker in tumor staging and prognosis by encompassing the tumor microenvironment. Front. Oncol. 2022, 12, 953091.
    [41]
    . Burger WAC, Draper-Joyce CJ, Valant C, Christopoulos A, Thal DM. Positive allosteric modulation of a GPCR ternary complex. Sci. Adv. 2024, 10, eadp7040.
    [42]
    . Zhang M, Chen T, Lu X, Lan X, Chen Z, Lu S. G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery. Signal Transduct Target Ther. 2024, 9, 88.
    [43]
    . Lynch JB, Gonzalez EL, Choy K, Faull KF, Jewell T, Arellano A, et al. Gut microbiota Turicibacter strains differentially modify bile acids and host lipids. Nat. Commun. 2023, 14, 3669.
    [44]
    . Kowal JM, Haanes KA, Christensen NM, Novak I. Bile acid effects are mediated by ATP release and purinergic signalling in exocrine pancreatic cells. Cell Commun. Signal. 2015, 13, 28.
    [45]
    . Wang Y, Xu H, Zhang X, Ma J, Xue S, Shentu D, et al. The role of bile acids in pancreatic cancer. Curr. Cancer Drug Targets. 2024, 24, 1005–1014.
    [46]
    . Lei Y, Li G, Li J, Gao S, Lei M, Gong G, et al. Investigation of the potential role of TGR5 in pancreatic cancer by a comprehensive molecular experiments and the liquid chromatography mass spectrometry (LC-MS) based metabolomics. Discov. Oncol. 2022, 13, 46.
    [47]
    . Di Giorgio C, Bellini R, Lupia A, Massa C, Bordoni M, Marchianò S, et al. Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma. Front. Oncol. 2023, 13, 1140730.
    [48]
    . Zhang GX, Zhan C, Wang K, Han J, Shang D, Chen HI. Qingyi Decoction amerliorates acute biliary pancreatitis by targeting Gpbar1/NF-kb pathway. Front. Biosci. 2019, 24, 833–848.
    [49]
    . Li W, Zou L, Huang S, Miao H, Liu K, Geng Y, et al. The anticancer activity of bile acids in drug discovery and development. Front. Pharmacol. 2024, 15, 1362382.
    [50]
    . Li W, Chen H, Tang J. Interplay between bile acids and intestinal microbiota: regulatory mechanisms and therapeutic potential for infections. Pathogens 2024, 13, 702.
    [51]
    . Simpson RC, Shanahan ER, Scolyer RA, Long GV. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 2023, 20, 697–715.
    [52]
    . Hu H, Shao W, Liu Q, Liu N, Wang Q, Xu J, et al. Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion. Nat. Commun. 2022, 13, 252.
    [53]
    . Yu L, Liu Y, Wang S, Zhang Q, Zhao J, Zhang H, et al. Cholestasis: exploring the triangular relationship of gut microbiota-bile acid-cholestasis and the potential probiotic strategies. Gut. Microbes. 2023, 15, 2181930.
    [54]
    . Zhang X, Shi L, Lu X, Zheng W, Shi J, Yu S, et al. Bile Acids and Liver Cancer: Molecular mechanism and therapeutic prospects. Pharmaceuticals 2024, 17, 1142.
    [55]
    . Yokota A, Fukiya S, Islam KB, Ooka T, Ogura Y, Hayashi T, et al. Is bile acid a determinant of the gut microbiota on a high-fat diet? Gut. Microbes. 2012, 3, 455–459.
    [56]
    . Wang S, Dong W, Liu L, Xu M, Wang Y, Liu T, et al. Interplay between bile acids and the gut microbiota promotes intestinal carcinogenesis. Mol. Carcinog. 2019, 58, 1155–1167.
    [57]
    . de Nies L, Kobras CM, Stracy M. Antibiotic-induced collateral damage to the microbiota and associated infections. Nat. Rev. Microbiol. 2023, 21, 789–804.
    [58]
    . Jaye K, Li CG, Chang D, Bhuyan DJ. The role of key gut microbial metabolites in the development and treatment of cancer. Gut. Microbes. 2022, 14, 2038865.
    [59]
    . Ridlon JM, Gaskins HR. Another renaissance for bile acid gastrointestinal microbiology. Nat. Rev. Gastroenterol Hepatol. 2024, 21, 348–364.
    [60]
    . Yang F, Mao C, Guo L, Lin J, Ming Q, Xiao P, et al. Structural basis of GPBAR activation and bile acid recognition. Nature 2020, 587, 499–504.
    [61]
    . Pathak P, Xie C, Nichols RG, Ferrell JM, Boehme S, Krausz KW, et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology. 2018, 68, 1574–1588.
    [62]
    . Zhai Z, Niu KM, Liu Y, Lin C, Wu X. The gut microbiota-bile acids-TGR5 axis mediates eucommia ulmoides leaf extract alleviation of injury to colonic epithelium integrity. Front. Microbiol. 2021, 12, 727681.
    [63]
    . Bidault-Jourdainne V, Merlen G, Glénisson M, Doignon I, Garcin I, Péan N, et al. TGR5 controls bile acid composition and gallbladder function to protect the liver from bile acid overload. JHEP Rep. 2021, 3, 100214.
    [64]
    . Lerch MM, Aghdassi AA. The role of bile acids in gallstone-induced pancreatitis. Gastroenterology 2010, 138, 429–433.
    • Related Articles

  • Related Articles

    [1]Pingping Sun, Xuemin Cao, Yuanlin Liu, Lizhou Jia. Eg5 high expression predicts dismal prognosis in epithelial ovarian cancer[J]. Blood&Genomics, 2019, 3(2): 145-151. DOI: 10.46701/APJBG.2019022019128
    [2]Baolan Hao, Hengwei Zhang, Yu-ping Ye, Xinjian Hao, Yan Wang. Coagulation status detection in breast cancer patients by using thrombelastography[J]. Blood&Genomics, 2018, 2(4): 249-253. DOI: 10.46701/APJBG.2018042018130
    [3]Yuanlin Liu, Shuang Liu, Yingjing Wang, Min Su, Yuquan Zhang, Xiaoqin Liu, Feng Yao, Yunzhao Xu. HMP19 is a new metastasis suppressor in epithelial ovarian cancer[J]. Blood&Genomics, 2018, 2(3): 177-182. DOI: 10.46701/APJBG.2018032018112
    [4]Lizhou Jia, Xiaobing Yang, Wei Zhao. β-catenin is up-expressed and predicts poor overall survival of breast cancer[J]. Blood&Genomics, 2018, 2(2): 111-116. DOI: 10.46701/APJBG.2018022018007
    [5]Huan Wang, Xiaojun Tang, Xin Xu, Chu Chu, Siping Xiong, Feng Zheng, Qisong Peng. The establishment of human anti-TROP2 antibody IgG and its inhibition function on pancreatic cancer cell proliferation[J]. Blood&Genomics, 2017, 1(4): 65-71. DOI: 10.46701/APJBG.2017042017045
    [6]Ziyi He, Jialin Che. Development and application of electronic crossmatch in Dongguan city[J]. Blood&Genomics, 2017, 1(4): 37-41. DOI: 10.46701/APJBG.2017042017053
    [7]Zhidan Tian, Yongya Ren, Xiaohong Qi. miR-34a is associated with clinical outcome of colorectal cancer patients[J]. Blood&Genomics, 2017, 1(3): 33-37. DOI: 10.46701/APJBG.2017032017038
    [8]Zequn Zheng, Qi Tang, Zhenqing Feng. CAR-T cell therapy and its application in clinical cancer treatment[J]. Blood&Genomics, 2017, 1(3): 1-6. DOI: 10.46701/APJBG.2017032017040
    [9]Qi Tang, Xingwang Kuai, Wei Zhao, Guipeng Ding, Zhenning Qiu, Zhuming Wang, Xiang Zou. The expression level of surface marker Trop2 in gastric cancer stem-like cells[J]. Blood&Genomics, 2017, 1(2): 61-66. DOI: 10.46701/APJBG.20170217031
    [10]Xiaohua Tu, Yan Zang, Haihui Gu, Huijun Guo, Xin Ye, Zhanshan Cha, Baohua Qian. Perioperative blood transfusion is associated with poorer survival in patients with gastric cancer[J]. Blood&Genomics, 2017, 1(2): 7-13. DOI: 10.46701/APJBG.20170217024

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (59) PDF downloads (9) Cited by()
    Related

    Copyright © Blood and Genomics苏公网安备 32028102000501号苏ICP备14047883号-6

    Address：Rooms 1318-19, Hollywood Plaza, 610 Nathan Road, Mongkok, Kowloon, HongKong

    E-mail：editorial_office@apjbg.com

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return